Cantor Fitzgerald Analysts Lift Earnings Estimates for VRTX

Key Points

• Cantor Fitzgerald analysts have raised their FY2025 earnings per share estimate for Vertex Pharmaceuticals to $15.65, up from $15.55, while maintaining an "Overweight" rating and a $485.00 price target.
• Vertex Pharmaceuticals reported $4.52 earnings per share for the last quarter, exceeding analysts' expectations of $4.24, with a revenue of $2.94 billion.
• Thirteen analysts have rated Vertex Pharmaceuticals as "hold" while fourteen have assigned a "buy" rating, indicating a consensus rating of "Moderate Buy" with an average price target of $497.10.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued on Tuesday, August 5th. Cantor Fitzgerald analyst C. Gould now forecasts that the pharmaceutical company will post earnings per share of $15.65 for the year, up from their prior forecast of $15.55. Cantor Fitzgerald currently has a "Overweight" rating and a $485.00 price target on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

Other analysts have also recently issued research reports about the stock. Stifel Nicolaus set a $455.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a "hold" rating in a report on Tuesday. Scotiabank lowered their target price on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating on the stock in a research note on Tuesday. Needham & Company LLC reissued a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Erste Group Bank cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Finally, UBS Group set a $553.00 target price on shares of Vertex Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday. Thirteen investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $497.10.

Vertex Pharmaceuticals Stock Up 2.8%

VRTX stock opened at $385.65 on Thursday. The company has a quick ratio of 2.29, a current ratio of 2.52 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a fifty-two week low of $372.35 and a fifty-two week high of $519.88. The firm's 50-day simple moving average is $453.73 and its 200 day simple moving average is $466.25. The stock has a market cap of $99.03 billion, a PE ratio of 27.57 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to analysts' expectations of $2.90 billion. During the same quarter last year, the company earned ($12.83) EPS. The company's revenue for the quarter was up 11.3% compared to the same quarter last year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of VRTX. Activest Wealth Management bought a new position in Vertex Pharmaceuticals during the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 45 shares during the period. Access Investment Management LLC bought a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $27,000. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $29,000. Finally, Mascagni Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the 4th quarter valued at $31,000. Institutional investors own 90.96% of the company's stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.